| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/29/2009 | CN100482253C Preparation with antler gelatin and epimeddium for treating mammary gland hyperplasia and preparation method thereof |
| 04/29/2009 | CN100482252C Medicinal composition for treating hepatitis B |
| 04/29/2009 | CN100482250C Externally used traditional Chinese medicine composition for treating dermatosis |
| 04/29/2009 | CN100482247C Improved process for producing liver-care prepns. |
| 04/29/2009 | CN100482246C Chinese herb medical preparation for treating diabetes and its preparation method |
| 04/29/2009 | CN100482244C Compound recipe medicine for treating apoplexy and its preparation method |
| 04/29/2009 | CN100482241C Quickly-acting defervescence plaster used for infants and preparation method thereof |
| 04/29/2009 | CN100482240C Compound preparation of Chinese traditional medicine for anticancer |
| 04/29/2009 | CN100482238C Cosmetics |
| 04/29/2009 | CN100482235C 2-glucoside Chinese medicinal oral preparation and its making method thereof |
| 04/29/2009 | CN100482231C Cefepime hydrochloride powder injection and preparing method thereof |
| 04/29/2009 | CN100482230C Method for preparing minoxidil tincture |
| 04/29/2009 | CN100482227C Sustained release compound capsules and its preparation method |
| 04/29/2009 | CN100482221C Use of nefopam for the treatment of nausea or emesis |
| 04/29/2009 | CN100482220C Oral preparation of bilobalide with high bioavailability and preparation method thereof |
| 04/29/2009 | CN100482217C Medical usage of 2beta-hydroxyilicicacid in inhibiting hepatitis B |
| 04/29/2009 | CN100482216C Use of hydroxide-releasing agents as skin permeation enhancers |
| 04/29/2009 | CN100482215C Effervesce tablet of pure American ginseng and preparation method |
| 04/29/2009 | CN100482214C Blood circulation promoting and pain relieving bolus and its prepn |
| 04/29/2009 | CN100482213C Monascus pellet and its preparing method |
| 04/29/2009 | CN100482212C Process for preparing nano liposome for coating large molecular medicine |
| 04/29/2009 | CN100482211C Medicinal targeted local lipolysis |
| 04/29/2009 | CN100482210C External applied Chinese medicinal paste for treating arthralgia |
| 04/29/2009 | CN100482209C Coal-tar externally-applied gel for treating psoriasis and its preparation |
| 04/29/2009 | CN100482208C Compound licorice medicine prepn and its prepn process |
| 04/29/2009 | CN100482207C Novel lipid mixtures for synthetic surfactants |
| 04/29/2009 | CN100482102C Homogeneous solid granules containing carotenoids |
| 04/28/2009 | US7524981 Phospholipid derivatives and process for the production there |
| 04/28/2009 | US7524911 Adhesive and marking compositions made from interpolymers of ethylene/α-olefins |
| 04/28/2009 | US7524834 Antiinflammatory and antiallergic glucocorticosteroid, sterile glucocorticosteroids |
| 04/28/2009 | US7524830 Decoy-containing pharmaceutical compositions and method of using the same |
| 04/28/2009 | US7524828 Immunostimulatory nucleic acid molecules |
| 04/28/2009 | US7524561 Coated water-swellable material |
| 04/28/2009 | US7524530 Combining exendin and sucrose with oil phase comprising glycolic acid-lactic acid copolymer in methylene chloride to form emulsion, which is combined with coacervation agent (silicone oil) to form microparticles, transferring to quenching solvent, then hardening; sustained release; shelf life |
| 04/28/2009 | US7524515 Antagonist has significant bioavailability only when said pharmaceutical safety dosage form is disrupted. |
| 04/28/2009 | US7524513 Polymeric fibers with conjugated biofunctional ligands and/or cell factors with biodegradation or nonbiodegradation fibers |
| 04/28/2009 | US7524512 Applying L-ascorbic acid in highly acidic concentration to middle ear |
| 04/28/2009 | US7524511 Method and kit for moisturizing the surface of the eye |
| 04/28/2009 | US7524484 Delivery of diphenhydramine through an inhalation route |
| 04/28/2009 | US7523821 Disposable package for liquid, pasty or powder product |
| 04/28/2009 | CA2497171C Water stabilized medicinal aerosol formulation |
| 04/28/2009 | CA2496864C A pharmaceutical composition |
| 04/28/2009 | CA2450949C Methods and compositions for polyene antibiotics with reduced toxicity |
| 04/28/2009 | CA2438199C Process for making microcapsules involving phase inversion |
| 04/28/2009 | CA2425314C Pharmaceutical compositions containing oxapenem-3-carboxylic acids |
| 04/28/2009 | CA2408245C Media milling |
| 04/28/2009 | CA2400176C Substituted piperazine compounds |
| 04/28/2009 | CA2394672C Biodegradable polymer composition |
| 04/28/2009 | CA2361716C Method of preparing alkylated salicylamides |
| 04/28/2009 | CA2361424C Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| 04/28/2009 | CA2360236C Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 04/28/2009 | CA2344686C High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one |
| 04/28/2009 | CA2339765C Compounds and compositions for delivering active agents |
| 04/28/2009 | CA2213476C Method for preparing a preparation for bleaching teeth, treating skin complaints, and mucous membrane disorders |
| 04/28/2009 | CA2212382C Cochleate delivery vehicles |
| 04/28/2009 | CA2197653C Delivery of nucleic acids |
| 04/28/2009 | CA2164838C A lotion comprising a tricyclic macrolide |
| 04/26/2009 | CA2641830A1 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
| 04/23/2009 | WO2009052519A2 Co-polymer stabilizers for hydrofluoroalkane dispersions |
| 04/23/2009 | WO2009052491A2 Fenoldopam formulations and prodrug derivatives |
| 04/23/2009 | WO2009052456A1 Film delivery system incorporating small scale actives |
| 04/23/2009 | WO2009052421A1 Composition for administering an active ingredient and method for making and using the same |
| 04/23/2009 | WO2009052391A1 Solid formulations of crystalline compounds |
| 04/23/2009 | WO2009052367A1 Micro- and nanoscale devices for delivery of active fibronolytic agents |
| 04/23/2009 | WO2009052353A2 Trospium pharmaceutical formulations |
| 04/23/2009 | WO2009052295A2 Cerium oxide nanoparticles for treatment and prevention of alzheimer's disease, parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction |
| 04/23/2009 | WO2009052251A1 Pharmaceutical solid hybrids |
| 04/23/2009 | WO2009052057A1 Use of gas-filled microbubbles for selective partitioning of cell populations and molecules in vitro and in vivo |
| 04/23/2009 | WO2009051992A1 Compositions and methods for treating diseases involving ocular angiogenesis by inhibiting one or more selected receptor tyrosine kinases |
| 04/23/2009 | WO2009051845A2 Biodegradable implants with controlled bulk density |
| 04/23/2009 | WO2009051805A1 Manufacturing solid pharmaceutical dosage forms with visible micro-and nanostructured surfaces and micro-and nanostructured pharmaceutical dosage form |
| 04/23/2009 | WO2009051794A1 Pharmaceutical moire pill |
| 04/23/2009 | WO2009051712A1 Dnai amphoteric liposome formulation |
| 04/23/2009 | WO2009051648A2 Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same |
| 04/23/2009 | WO2009051628A2 Transdermal treatment device and method |
| 04/23/2009 | WO2009051618A1 Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| 04/23/2009 | WO2009051517A1 Pharmaceutical composition in the form of microcapsulated multicomponent particles made of n-carbfmoyl-methyl-4-phenyl-2-pyrrolidone and an auxiliary neutral organic low-molecular component and method for microcapsulation thereof |
| 04/23/2009 | WO2009051451A2 Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| 04/23/2009 | WO2009051217A1 Fentanyl-containing percutaneous absorption preparation |
| 04/23/2009 | WO2009050726A2 Compositions and methods for improved delivery of bupropion |
| 04/23/2009 | WO2009050720A1 Pharmaceutical composition of orlistat |
| 04/23/2009 | WO2009050555A2 Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof |
| 04/23/2009 | WO2009050527A1 Pharmaceutical composition comprising s-nitrosoglutathione and polysaccharide |
| 04/23/2009 | WO2009050490A1 Oral composition comprising a cooling agent |
| 04/23/2009 | WO2009050483A1 Cationic lipids |
| 04/23/2009 | WO2009050479A1 Comestible products |
| 04/23/2009 | WO2009050403A2 Patch with hydrophilic adhesive |
| 04/23/2009 | WO2009050333A1 Microencapsulated liposomal compositions |
| 04/23/2009 | WO2009050291A2 Solid dispersion product of n-aryl urea-based drugs |
| 04/23/2009 | WO2009050289A2 Solid dispersion product containing n-aryl urea-based compound |
| 04/23/2009 | WO2009050217A2 Improved pharmaceutical dry powder compositions for inhalation |
| 04/23/2009 | WO2009050203A1 Solvent-free synthesis of amphiphilic polymeric material |
| 04/23/2009 | WO2009050192A1 Paneled capsule shells for release of pharmaceutical compositions |
| 04/23/2009 | WO2009050168A1 Drug-eluting nanowire array |
| 04/23/2009 | WO2009049911A1 Functionalised materials and uses thereof |
| 04/23/2009 | WO2009049820A2 Amorphous formulation |
| 04/23/2009 | WO2009049648A2 Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof |
| 04/23/2009 | WO2009049643A1 Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof |
| 04/23/2009 | WO2009049642A1 Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof |
| 04/23/2009 | WO2009049490A1 Use of aminoglycoside antibiotic in the preparation of pharmaceutical composition for treating drug-resistant bacterial infection |